Navigation Links
MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Date:3/18/2008

- Company Initiates Phase 2a Trial in Patients with Stable Asthma and

Exercise-Induced Bronchoconstriction -

GAITHERSBURG, Md., March 18 /PRNewswire/ -- MedImmune today announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma. The company initiated a Phase 2a clinical trial designed to assess the potential of its anti-IL-9 monoclonal antibody (MAb), MEDI-528, in patients with stable asthma and exercise-induced bronchoconstriction. This trial is the fourth study of this antibody in patients with asthma.

"Commencing this trial is a promising step in the clinical development of MEDI-528, as preclinical data has suggested that blocking IL-9 may provide clinical benefit for patients with asthma," said Barbara White, vice president, clinical development, inflammatory disease. "We look forward to continuing to work with our network of collaborative researchers to discover and assess novel pathologies and approaches to inflammatory diseases."

The goal of this clinical trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction. The study will also assess the effect of the antibody on exercise challenge testing, as well as the pharmacokinetics and immunogenicity of the investigational treatment. Enrollment of this randomized, double-blind, placebo-controlled trial has commenced at Northeast Medical Research Associates, Inc. and the study is expected to expand to additional sites throughout the United States and Canada. Preliminary safety results from an ongoing Phase 2 trial support the continued development of the antibody in patients with mild-to-moderate asthma.

About Interleukin-9

IL-9 has been associated with symptoms of asthma. It is one of at least 29 naturally occurring interleukins
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
2. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
3. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
10. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, RALEIGH,N.C.,Nov.24/PRNewswire/--Pharmace...ingsolutionsforthepharmaceuticalandbiotechindustry...italMarketplace .Thenew HospitalMarketplace e-cour...Excellence(TM) series,acomprehensiveseriesofe-cour...dmanagedmarketsknowledgeforcommercialprofessionals...
(Date:11/24/2009)...,, HOLMDEL,N.J.,Nov.24/PRNewswire/--SpartaSy...leaderinenterprisequalityandcompliancesolutions,to...ingconsumerproductcompanyandtheparentcompanyforglo...ivewithTrackWiseEnterpriseQualityManagementSystem(...oharmonizeandstreamlinequalityoperationsthatinclud...
(Date:11/24/2009)...,, SALTLAKECITY,Nov.24/PRNewswire/-- Infinit...thelaunchofanewonlinevisiontherapyprogrameyeQ,thes...n-officetherapymethods. ,, eyeQ wasintroduceda...ustrypresidentelect,Dr.BradHabermehlbelievesthe ey...yLearningCenterinFlintMichigan.Itallowshispatients...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2At the fungal farmers market only the best cyanobacteria are for sale 9661 1At the fungal farmers market only the best cyanobacteria are for sale 9661 2Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 1Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 2Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 1Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 2
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
(Date:11/24/2009)...Call/-HardtoTreatDiseases(HTDS; http://www.htdsmed...,isprovidingthisbriefupdatetoitsfollowersandshareh...Ustemcellcompanyandmergerdiscussions.Thisrelatesto...companymade. http://www.pinksheets.com/pink/quote/...caBiochemarealsodiscussingonexpandingtheresearchto...
(Date:11/24/2009)...TheAmericanDentalAssociation(ADA)hassignedanagreem...aspartofapilotprogramtoimprovetheoralhealthinunder...oordinator(CDHC)isamemberofthedentalhealthteamwhow...dentalcaretoimprovetheiroralhealth. ,, TheCDHCp...--includingscreeningsandfluoridetreatments.However...
(Date:11/24/2009)...Thereisanewgameintownwhenitcomestodealingwithalcoh...ealisticstrategieswheretraditionalapproachestoalco...roupcalledHAMS--HarmReduction,AlcoholAbstinenceand...portandinformationalgroupforpeoplewhodrinkalcohol....lismtellsusthatonly7%ofpeoplewithanalcoholprobleme...
(Date:11/24/2009)...N,LA,ME,NE,NDandSD ,, ALEXANDRIA,Va.,Nov.24/PR...onSaturdaytotakeupthehealthcarereformlegislation,t...mpaigntargetingSenatorsinninestates-Alaska,Arkansa...kota,andSouthDakota. ,, The$2.0millionadbuyhigh...reportwhichconfirmscutstoMedicareofhalfatrilliondo...
(Date:11/24/2009)...LifeInsuranceCompanyofAmerica(Guardian),oneofthela...eebenefitsforsmallandmid-sizedcompanies,todayannou...surancecoverageguidelinesformammographyscreenings....ocietyandAmericanMedicalAssociation(AMA)recommenda....S.PreventiveServicesTaskForcerecommendedincreasin...
Breaking Medicine News(10 mins):Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3Health News:ADA Launches Community Dental Health Coordinator Pilot Program at Temple University 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
Glucose UV Liquidplus
Glucose Color Liquidplus Reagent
Glucose (Oxidase)
Glucose (Hexokinase)
Medicine Products: